Ordspono (Odronextamab)

Ordspono is a bispecific antibody that targets the CD20 pathway in B‑cell malignancies.

• Relapsed or refractory large B‑cell lymphoma: provides an option for patients who have exhausted standard therapies.
• Follicular lymphoma: used in adults with disease that has progressed after prior treatments.
• Diffuse large B‑cell lymphoma: offers a therapeutic alternative when conventional chemo‑immunotherapy fails.

• Odronextamab is a bispecific T‑cell engager that simultaneously binds CD20 on B‑cells and CD3 on T‑cells. This dual binding brings cytotoxic T‑cells into close proximity with malignant B‑cells, triggering T‑cell activation, proliferation, and targeted cell death, thereby reducing tumor burden.

Adverse reactions to Ordspono vary in frequency and severity.

Common Side Effects

• Cytokine release syndrome: fever, chills, hypotension, or tachycardia.
• Fatigue: persistent tiredness not relieved by rest.
• Nausea: mild to moderate upset stomach.
• Diarrhea: loose stools occurring intermittently.
• Headache: mild to moderate head pain.
• Infusion‑related reactions: redness, itching, or swelling at the site.

Serious or Rare Side Effects

• Severe cytokine release syndrome: life‑threatening systemic inflammation.
• Neurotoxicity: confusion, seizures, or altered mental status.
• Infections: opportunistic or severe bacterial, viral, or fungal infections.
• Hematologic toxicity: severe neutropenia or thrombocytopenia.
• Cardiac events: arrhythmias or myocardial infarction.
• Anaphylaxis: rapid onset allergic reaction requiring emergency care.

When handling Ordspono, clinicians should observe several safety measures.

• Patient assessment: evaluate disease status and prior therapies before initiation.
• Monitoring: conduct regular laboratory and clinical monitoring for cytokine release syndrome and infections.
• Dose adjustments: modify dosing if severe toxicities develop.
• Contraindications: avoid use in patients with known hypersensitivity to odronextamab or its excipients.
• Pregnancy and lactation: weigh potential benefits against risks; limited data are available.
• Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Odronextamab may interact with other medicines, requiring careful management.

Major Interactions (Avoid)

• Live vaccines: concurrent administration can increase risk of severe infection.
• Strong immunosuppressants: may diminish therapeutic efficacy of odronextamb.

Moderate Interactions (Monitor Closely)

• CYP450 substrates: monitor levels as odronextamab may alter immune‑mediated drug clearance.
• Anticoagulants: observe for increased bleeding risk during cytokine release events.
• Concomitant monoclonal antibodies: assess additive immunosuppression.
• Corticosteroids: may mask early signs of cytokine release syndrome.
• Herbal supplements affecting immunity: evaluate for potential synergistic effects.